Imbria Pharmaceuticals secured investment from AXA IM Alts in an upsized Series B round to enhance clinical development of ninerafaxstat, aiming at serious cardiovascular diseases.
Round Type
Series B
BostonBiotechnologyHealth CareInvestors
Description
Imbria Pharmaceuticals, Inc., a Boston-based clinical-stage company, has received investment from AXA IM Alts in an upsized Series B financing. This investment includes prominent investors such as RA Capital and SV Health Investors. The funds will aid in the clinical development of ninerafaxstat, Imbria’s cardiotherapy. The lead investors' involvement highlights the confidence in Imbria’s groundbreaking approach.
Quick answer
Imbria Pharmaceuticals raised an undisclosed amount in a Series B round, dated November 19, 2025. Investors: Cytokinetics, Inc., Cytokinetics, Catalio Capital Management, AN Ventures, Deep Track Capital, SV Health Investors, RA Capital and Axa Im Alts. Imbria Pharmaceuticals is based in Boston, Massachusetts, United States.
- How much did Imbria Pharmaceuticals raise?
- Imbria Pharmaceuticals raised an undisclosed amount in a Series B round on November 19, 2025.
- Who invested in Imbria Pharmaceuticals?
- Cytokinetics, Inc., Cytokinetics, Catalio Capital Management, AN Ventures, Deep Track Capital, SV Health Investors, RA Capital and Axa Im Alts are named as investors in this round.
- What does Imbria Pharmaceuticals do?
- Imbria is a privately held, clinical stage company developing novel therapies for patients with life-altering cardiometabolic disorders.
- Where is Imbria Pharmaceuticals based and how big is it?
- Imbria Pharmaceuticals is based in Boston, Massachusetts, United States.
- Who are the decision-makers at Imbria Pharmaceuticals?
- Fundz holds 1 contact at Imbria Pharmaceuticals. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology and Health Care around the same time
Companies in the same sectors as Imbria Pharmaceuticals that raised within 45 days of this round, from Fundz verified event records.
- PrognomiQ raised $12M on January 2, 2026.
- Navega Therapeutics raised $1.3M (Seed) on January 2, 2026.
- SCA Health raised $412K (Seed) on December 31, 2025.
- iSpecimen raised $5.5M (Series C) on December 30, 2025.
- Biobeat Technologies raised $50M (Series B) on December 30, 2025.
- Harvard Apparatus Regenerative Technology raised $700K on December 30, 2025.
Who to call at Imbria Pharmaceuticals, and when
A new round usually means Imbria Pharmaceuticals is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Imbria Pharmaceuticals raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Imbria Pharmaceuticals, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Imbria Pharmaceuticals. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Imbria Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansImbria Pharmaceuticals raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.